Clinical trials
Tolerance clinical trials
Below are recruiting tolerance clinical trials, each written for real people, not researchers. We’re tracking 942 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07005713RecruitingPhase 1
Study of tacabrutideg for chronic spontaneous urticaria
This trial tests a new oral medication called tacabrutideg (BGB-16673) for chronic spontaneous urticaria, a condition with frequent hives and itching. It aims to see how safe it is and how well it works, possibly offering a new option for people who still have symptoms despite antihistamines.
Beijing, Beijing MunicipalityAges 18–70 - NCT07007637Enrolling by invitationPhase 3
Long-Term Safety and Effectiveness of Sonelokimab for Hidradenitis Suppurativa
This study offers long-term treatment with an investigational biologic, sonelokimab, for people with moderate to severe hidradenitis suppurativa who finished an earlier sonelokimab study. The goal is to see if sonelokimab remains safe and effective over time.
Birmingham, AlabamaAges 12 years+ - NCT07011511RecruitingPhase 1
Testing a new malaria drug in healthy volunteers
This trial tests a new malaria drug (MMV055), alone or with another drug (MMV371), to see if it is safe and how the body processes it. It is for healthy people who want to help find new malaria treatments.
NottinghamAges 18–60 - NCT06618313Recruiting
Testing JCXH-213 for B-cell lymphoma that returned or didn't respond
This trial tests a new treatment called JCXH-213 for people with B-cell non-Hodgkin lymphoma that came back or didn't get better after previous treatment. It aims to see if the treatment is safe and works against the cancer.
BeijingAges 18 years+ - NCT06995482RecruitingPhase 1
Testing safety of KSHN001034 in healthy postmenopausal women
This study tests how safe and tolerable a new drug, KSHN001034, is in healthy women who have gone through menopause. It involves multiple doses to see how your body processes the medicine.
Miami Lakes, FloridaAges 45–60 - NCT06995573RecruitingPhase 1/Phase 2
Testing a new Alzheimer's drug (NSC001) for safety and early effectiveness
This study tests a new drug called NSC001 for people with mild to moderate Alzheimer's. It checks if the drug is safe and if it might help slow memory decline. You'll need a caregiver who can join you at visits and help track your progress.
Salzburg, State of SalzburgAges 50–85 - NCT06994845RecruitingPhase 3
Testing iptacopan for children with IgA nephropathy
This study tests a new medicine called iptacopan to see if it helps children with IgA nephropathy (a kidney disease). Kids who join will receive the study treatment and be monitored for safety and effectiveness.
Madera, CaliforniaAges 2–18 - NCT06994897RecruitingPhase 1
Safety and dosing study of PF-07985631 in healthy adults
This study tests a new medicine called PF-07985631 in healthy adults to see how different amounts are tolerated and processed by the body. It includes specific groups for Japanese and Chinese participants.
Brussels, Bruxelles-capitale, Région deAges 18–55 - NCT06987539RecruitingPhase 2
Inebilizumab for children with generalized myasthenia gravis
This study tests a new drug called inebilizumab for children with generalized myasthenia gravis (gMG), a condition causing muscle weakness. The drug aims to reduce the immune system's attack on nerves, which may improve symptoms. The study will check how safe and effective it is for young patients.
Philadelphia, PennsylvaniaAges 2–17 - NCT06989840RecruitingPhase 1
Safety study of TVB-3567 for acne
This early-stage study tests a new drug called TVB-3567, which may help treat acne. It checks the drug's safety and how the body processes it, first in healthy people and then in people with moderate to severe acne.
Tempe, ArizonaAges 18–55 - NCT06515470RecruitingPhase 1
Testing BTX-9341 for advanced breast cancer
This trial tests a new oral drug, BTX-9341, for people with advanced or metastatic hormone receptor-positive, HER2-negative breast cancer who have already had certain treatments, including a CDK4/6 inhibitor. The goal is to see if it is safe and effective.
Rochester, MinnesotaAges 18 years+ - NCT06980948RecruitingPhase 1/Phase 2
Gene therapy study for nerve pain from small fiber neuropathy
This trial tests a new gene therapy called ST-503 for people with long-lasting nerve pain from small fiber neuropathy that hasn't improved with standard treatments. The study will check if the treatment is safe and tolerable.
Scottsdale, ArizonaAges 18 years+ - NCT06976268RecruitingPhase 2/Phase 3
Testing BHV-8000 for early Parkinson's disease
This study tests a new once-daily pill called BHV-8000 in people who were recently diagnosed with early Parkinson's disease and are not yet on medication. The goal is to see if it can slow the progression of symptoms and improve quality of life.
Birmingham, AlabamaAges 40–80 - NCT06978920RecruitingPhase 1
Stem cell therapy for Parkinson's disease
This early-stage trial tests a new stem cell treatment called NCR201 for people with Parkinson's. It aims to see if the treatment is safe and might help improve symptoms.
Hefei, AnhuiAges 40–75 - NCT06980428RecruitingPhase 1
Safety study of AZD4954 in people with or without high Lp(a)
This trial tests a new drug called AZD4954 for safety. It includes healthy volunteers and people with high Lp(a) or dyslipidemia. The goal is to see if the drug is safe and how the body processes it.
Glendale, CaliforniaAges 18–70 - NCT06975618RecruitingPhase 1/Phase 2
Study of CYH33 for PIK3CA-related overgrowth and vascular malformations
This trial tests a new drug called CYH33 for people with conditions caused by a specific gene mutation (PIK3CA) that leads to abnormal tissue growth or blood vessel problems. It aims to see if the drug is safe and can help shrink or control these growths.
Beijing, Beijing MunicipalityAges Any age - NCT06976892RecruitingPhase 1
Idetrexed and Olaparib for ovarian cancer
This trial tests two drugs, idetrexed and olaparib, in people with a type of ovarian cancer that has stopped responding to standard treatments. It aims to see if this combination can help shrink or control the cancer.
Cambridge, CambridgeshireAges 18 years+ - NCT06977269Recruiting
Brain stimulation safety study for spinal muscular atrophy
This trial tests whether a non-invasive brain stimulation technique called transcranial magnetic stimulation (TMS) is safe and tolerable for people with spinal muscular atrophy (SMA). It may help improve muscle function by activating low motor neurons.
Kharkiv, Kharkiv OblastAges 12 years+ - NCT06968494Recruiting
Implantable device to preserve erections after prostate surgery
This trial tests a new implantable device designed to help men keep their erections after nerve-sparing prostate surgery. If you are having surgery for early-stage prostate cancer and have good erectile function now, this device might help you maintain it.
Baltimore, MarylandAges 30–75 - NCT06966401RecruitingPhase 3
Long-term safety study of a new depression treatment
This study tests a new oral medication (NBI-1065845) added to your current antidepressant to see if it's safe and tolerable over a long period for people with depression that hasn't fully responded to treatment.
Huntsville, AlabamaAges 18 years+ - NCT06969430RecruitingPhase 1/Phase 2
Debio 1562M for relapsed or refractory AML
This trial tests a new drug called Debio 1562M for people with AML that has not responded to treatment or has come back. It aims to see if the drug is safe and can help fight the leukemia.
Duarte, CaliforniaAges 18 years+ - NCT06969170RecruitingPhase 2
Psilocybin oral solution for generalized anxiety disorder trial
This study tests a psilocybin oral solution in adults with generalized anxiety disorder (GAD). It aims to see if the drug is safe, tolerable, and helpful for reducing anxiety symptoms.
Kingston, OntarioAges 18–60 - NCT06043193Recruiting
Quality of life study for patients with neuroendocrine tumors getting internal radiation therapy
This study looks at how internal radiation therapy (RIV) affects quality of life in people with neuroendocrine tumors. It aims to understand how well patients tolerate this treatment and how it impacts daily life.
Saint-Priest-en-Jarez, Saint-EtienneAges 18 years+ - NCT06955988RecruitingPhase 1
Safety and early results of AST2303 for advanced lung cancer
This trial tests a new oral drug, AST2303 (ABK3376), in people with advanced non-small cell lung cancer that has not responded to other treatments. It aims to see if the drug is safe and whether it can shrink tumors.
Shanghai, Shanghai MunicipalityAges 18 years+
Hear when a new Tolerance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tolerance?
- Yes. Clin2 currently lists 942 recruiting tolerance studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tolerance trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tolerance trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.